LifeSci Capital analyst Rahul Rakhit maintained a Buy rating on Akili (AKLI – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.06.
Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Orchestra BioMed Holdings, and Better Therapeutics, Inc.. According to TipRanks, Rakhit has an average return of -53.4% and a 2.17% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akili with a $3.38 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $37.58 and a one-year low of $0.86. Currently, Akili has an average volume of 173K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Social Capital Suvretta Holdings Corp I is a blank check company.
Read More on AKLI:
